tradingkey.logo

Sanofi SA

SNY

47.655USD

+0.445+0.94%
取引時間 ET15分遅れの株価
116.00B時価総額
17.08直近12ヶ月PER

Sanofi SA

47.655

+0.445+0.94%
詳細情報 Sanofi SA 企業名
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
企業情報
企業コードSNY
会社名Sanofi SA
上場日Jul 01, 2002
最高経営責任者「CEO」Mr. Paul Hudson, Ph.D.
従業員数84587
証券種類Depository Receipt
決算期末Jul 01
本社所在地46 Avenue de la Grande Armee
都市PARIS
証券取引所NASDAQ Global Select Consolidated
France
郵便番号75017
電話番号33153774000
ウェブサイトhttps://www.sanofi.com/
企業コードSNY
上場日Jul 01, 2002
最高経営責任者「CEO」Mr. Paul Hudson, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Ms. Clotilde Delbos
Ms. Clotilde Delbos
Independent Director
Independent Director
--
--
Mr. Frederic Oudea
Mr. Frederic Oudea
Independent Chairman of the Board
Independent Chairman of the Board
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
データなし
地域別USD
会社名
収益
比率
United States
4.90B
47.06%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
2.62B
25.20%
Europe
2.15B
20.65%
China
737.01M
7.08%
事業別
地域別
データなし
株主
更新時刻: Wed, Aug 6
更新時刻: Wed, Aug 6
株主統計
種類
株主統計
株主統計
比率
Dodge & Cox
3.01%
Fisher Investments
0.56%
Invesco Advisers, Inc.
0.47%
T. Rowe Price Associates, Inc.
0.45%
Capital World Investors
0.34%
Other
95.17%
株主統計
株主統計
比率
Dodge & Cox
3.01%
Fisher Investments
0.56%
Invesco Advisers, Inc.
0.47%
T. Rowe Price Associates, Inc.
0.45%
Capital World Investors
0.34%
Other
95.17%
種類
株主統計
比率
Investment Advisor/Hedge Fund
5.46%
Investment Advisor
4.38%
Research Firm
0.73%
Hedge Fund
0.19%
Bank and Trust
0.07%
Family Office
0.02%
Pension Fund
0.02%
Other
89.13%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
1261
264.33M
10.86%
-14.23M
2025Q1
1286
268.29M
10.62%
-13.21M
2024Q4
1263
270.44M
10.70%
-30.67M
2024Q3
1239
286.03M
11.43%
-5.72M
2024Q2
1248
275.46M
11.01%
-5.50M
2024Q1
1232
261.25M
10.33%
-7.62M
2023Q4
1213
251.25M
9.93%
-18.33M
2023Q3
1178
256.18M
10.15%
-15.97M
2023Q2
1173
257.65M
10.20%
-26.92M
2023Q1
1174
268.83M
10.66%
-6.19M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Dodge & Cox
73.19M
2.9%
-2.03M
-2.70%
Mar 31, 2025
Fisher Investments
13.57M
0.54%
+1.06M
+8.43%
Mar 31, 2025
Invesco Advisers, Inc.
11.37M
0.45%
-3.25K
-0.03%
Mar 31, 2025
T. Rowe Price Associates, Inc.
11.03M
0.44%
+193.02K
+1.78%
Mar 31, 2025
Capital World Investors
8.32M
0.33%
+8.32M
--
Mar 31, 2025
Managed Account Advisors LLC
7.57M
0.3%
-172.21K
-2.22%
Mar 31, 2025
Barrow Hanley Global Investors
7.35M
0.29%
-347.84K
-4.52%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.68M
0.19%
-269.36K
-5.45%
Mar 31, 2025
Wellington Management Company, LLP
4.43M
0.18%
-56.88K
-1.27%
Mar 31, 2025
Parametric Portfolio Associates LLC
4.04M
0.16%
+132.91K
+3.40%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Wed, Aug 6
更新時刻: Wed, Aug 6
銘柄名
比率
VanEck Pharmaceutical ETF
3.29%
Invesco International Dividend Achievers ETF
2.72%
Putnam Focused Large Cap Value ETF
2.05%
Brandes US Value ETF
1.98%
Altrius Global Dividend ETF
1.71%
ProShares Ultra Nasdaq Biotechnology
1.52%
American Century Focused Large Cap Value ETF
1.32%
Invesco Nasdaq Biotechnology ETF
1.26%
Invesco ESG NASDAQ Next Gen 100 ETF
0.99%
Invesco NASDAQ Next Gen 100 ETF
0.82%
詳細を見る
VanEck Pharmaceutical ETF
比率3.29%
Invesco International Dividend Achievers ETF
比率2.72%
Putnam Focused Large Cap Value ETF
比率2.05%
Brandes US Value ETF
比率1.98%
Altrius Global Dividend ETF
比率1.71%
ProShares Ultra Nasdaq Biotechnology
比率1.52%
American Century Focused Large Cap Value ETF
比率1.32%
Invesco Nasdaq Biotechnology ETF
比率1.26%
Invesco ESG NASDAQ Next Gen 100 ETF
比率0.99%
Invesco NASDAQ Next Gen 100 ETF
比率0.82%
配当金
過去5年間の配当金総支払額は 23.51B 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
tradingkey.logo
tradingkey.logo
当社が提供する日中データはRefinitivより配信されており、同社の利用規約が適用されます。終値データ(過去・現在)についてもRefinitivより提供されています。全ての相場情報は現地取引所時間で表示されます。米国株式のリアルタイム最終取引価格はNasdaqを通じて報告された取引のみを反映しています。日中データは最低15分遅れ、または各取引所の要件に準じて遅延配信されます。
* 当コンテンツ(分析資料・取引戦略等)は第三者プロバイダーであるTrading Centralより提供されており、記載の見解は分析官の独立した評価及び判断に基づくものです。投資家個々の投資目的や財務状況は考慮されておりません。
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。
KeyAI